Evaluation of clinical characteristics, health care resource utilization, and cost outcomes of hemophilia A carriers and noncarriers in the United States: A real-world comparative analysis.
Xing S, Batt K, Kuharic M, Bullano M, Caicedo J, Chakladar S, Markan R, Farahbakhshian S.
Xing S, et al.
J Manag Care Spec Pharm. 2023 Jun;29(6):626-634. doi: 10.18553/jmcp.2023.29.6.626.
J Manag Care Spec Pharm. 2023.
PMID: 37276033
Free PMC article.
These data suggest that hemophilia A carriers have a high disease and economic burden and may benefit from early diagnosis and management to prevent long-term complications. DISCLOSURES: Dr Xing, Dr Bullano, Dr Caicedo, and Mr Farahbakhshian are employees of Takeda Pharmac …
These data suggest that hemophilia A carriers have a high disease and economic burden and may benefit from early diagnosis and management to …